12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds.
Voyager Therapeutics Inc. (VYGR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 4,236,000 | $35,751,840 | +2% | 0.48% |
| 2. | EcoR1 Capital Oleg Nodelman | 3,851,507 | $32,506,719 | 0.84% | |
| 3. | Farallon Capital Thomas Steyer | 1,292,000 | $10,904,480 | 0.05% | |
| 4. | AQR Capital Management Cliff Asness | 639,287 | $5,395,582 | +222% | 0.01% |
| 5. | D E Shaw D. E. Shaw | 406,044 | $3,427,011 | -36% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.88 | 4,395,588 | Large Shareholder | 8,575,316 | 2023-02-23 | Filing | |
| $5.66 | 376,000 | Large Shareholder | 4,753,907 | 2022-06-23 | Filing | |
| $5.28 | 101,400 | Large Shareholder | 4,377,907 | 2022-06-21 | Filing | |
| $11.96 | 4,179,728 | Large Shareholder | 4,179,728 | 2019-03-12 | Filing | |
| $19.39 | 3,000 | Director | 76,588 | 2018-09-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.88 | 1,357 | Officer | 117,004 | 2024-04-02 | Filing | |
| $9.86 | 12,115 | Officer, Director | 322,839 | 2024-04-02 | Filing | |
| $7.45 | 3,966 | Officer | 118,361 | 2024-02-21 | Filing | |
| $7.46 | 13,033 | Officer, Director | 334,954 | 2024-02-21 | Filing | |
| $7.46 | 3,764 | Officer | 175,669 | 2024-02-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,632,679 | $22,219,809 | 0% | |
| 2. | 2,529,668 | $21,350,398 | 0% | |
| 3. | 932,231 | $7,868,732 | 0% | |
| 4. | 678,878 | $5,730,350 | 0% | |
| 5. | 619,812 | $5,231,213 | 0% |
News See All
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Earnings Call Transcript
Voyager Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.25, expectations were $-0.59. Voyager Therapeutics, Inc.
12 Best Healthcare Stocks For the Long-Term
In this piece, we will take a look at the 12 best healthcare stocks for the long term.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2023 Conference Call. All participants are now in a listen-only mode.
11 Most Undervalued Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 11 most undervalued biotech stocks to buy according to analysts.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to Voyager Therapeutics Second Quarter 2023 Conference Call. All participants are now in a listen-only mode.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q1 2023 Earnings Call Transcript
Operator: Good morning and welcome to Voyager Therapeutics First Quarter 2023 Conference Call. All participants are now in listen-only mode.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2022 Earnings Call Transcript
Operator: Good morning and welcome to Voyager Therapeutics 2022 Fourth Quarter and Year End Conference Call. All participants are now in listen-only mode.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2022 Earnings Call Transcript
Operator: Good morning, and welcome to Voyager Therapeutics Third Quarter 2022 Conference Call. All participants are now in a listen-only mode.
5 Best Biotech Stocks Under $5
NuCana plc (NASDAQ:NCNA) is a UK-based biotech company focused on discovering treatments for different types of cancer.
Billionaire Hedge Funds
